Desde PHI ORGANICS te hemos preparado este espacio donde podrás encontrar estudios sobre los cannabinoides, bibliografía y  enlaces a sitios de interés

 

Todavía seguimos trabajando en esta sección para seguir aportándote más conocimiento. En breve podrás disfrutar de más contenidos.

 

BIBLIOTECA DIGITAL 

 

Informe sobre el Cannabidiol -CBD : OMS (Organización Mundial de la Salud) https://medcan.es/pdf/informe-oms-cannabidiol.pdf 

 

Guía básica sobre los cannabinoides: SEIC (Sociedad Española de Investigación sobre cannabinoides) https://www.seic.es/wp-content/uploads/2013/10/guiabásicacannab.pdf

 

Efectos Terapéuticos de los Cannabinoides https://www.seic.es/wp-content/uploads/2013/10/EFECTOS-TERAPÉUTICOS-DE-LOS-CANNABINOIDES.pdf

 

Actualización sobre el potencial terapéutico de los Cannabinoides  https://www.seic.es/wp-content/uploads/2013/10/actualizacion-potencial-terapeutico-cannab.pdf

 

 

VIDEOTECA DIGITAL

Ekaitz Agirregoitia: Cannabinoides en Enfermedades Digestivas Inflamatorias

Ekaitz Agirregoitia es licenciado en Biología Sanitaria por la UCM desde 2003, Doctor en Biología por la UPV/EHU desde 2008 y profesor agregado del Departamento de Fisiología de la Facultad de Medicina y Odontología de la UPV/EHU desde 2012. Su área de investigación principal versa sobre el papel del sistema endocannabinoide en la fisiología de la reproducción tanto en el humano como en modelos animales. Colabora con Dosemociones en el grupo de pacientes con enfermedades inflamatorias intestinales (sobre todo enfermedad de Crohn y colitis ulcerosa) consumidores de cannabis con fines terapéuticos.

Manuel Guzmán: “Aplicaciones terapéuticas del cannabis y los cannabinoides”

Conferencia ofrecida el 5 de marzo de 2019 durante la jornada “Cannabis medicinal en el control del dolor crónico. La experiencia canadiense”, organizada por el Observatorio Español de Cannabis Medicinal en el Ilustre Colegio Oficial de Médicos de Madrid.

Manuel Guzmán es Catedrático de Bioquímica y Biología Molecular en la Universidad Complutense de Madrid. Sus investigaciones se centran en dilucidar cómo los cannabinoides afectan al funcionamiento y desarrollo de las células del sistema nervioso, y cómo pueden ayudar en la lucha contra enfermedades neurodegenerativas.

Carlos Goicoechea: “Cannabis y cannabinoides en dolor: experiencia preclínica”

Conferencia ofrecida el 5 de marzo de 2019 durante la jornada “Cannabis medicinal en el control del dolor crónico. La experiencia canadiense”, organizada por el Observatorio Español de Cannabis Medicinal en el Ilustre Colegio Oficial de Médicos de Madrid.

Carlos Goicoechea es Biólogo. Catedrático de Farmacología en la Universidad Rey Juan Carlos. Coordinador del Grupo de Excelencia Investigadora URJC-Santander “Grupo Multidisciplinar de Investigación y Tratamiento del Dolor”. Autor de 52 artículos en revistas internacionales, investigador en 52 proyectos y contratos (7 de ellos como investigador principal), 83 participaciones en congresos nacionales (45 como ponente invitado) y 103 en internacionales (16 como ponente invitado), 15 Tesis Doctorales dirigidas, 9 premios de investigación (2 internacionales). Vocal del CEIC del Hospital Universitario Fundación Alcorcón. Evaluador para la Agencia Nacional de Evaluación y Prospección (ANEP) y para el Instituto de Salud Carlos III (FIS). Secretario de la Sociedad Madrileña del Dolor.

ESTUDIOS Y REFERENCIAS

 

En este espacio ponemos a vuestra disposición algunos de los estudios y publicaciones relacionadas con el CBD publicadas hasta la fecha.

Esto son sólo algunos ejemplos que muestran la evidencia científica que existe a día de hoy.

 

CBD OVERVIEW

 

 

 

 

 

 

 

CBD Y MODULACIÓN DEL SUEÑO

 

  • Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. J Clin Pharm Ther. 2014 Oct 1 [cited 2021 Mar 2];39(5):564–6. Chagas MHN, Eckeli AL, Zuardi AW, Pena-Pereira MA, Sobreira-Neto MA, Sobreira ET, et al. http://doi.wiley.com/10.1111/jcpt.12179

 

  • The Endocannabinoid System May Modulate Sleep Disorders in Aging. Curr Neuropharmacol. PubMed. 2019 Aug 1 [cited 2021 Mar 3];18(2):97–108. Murillo-Rodríguez E, Budde H, Veras AB, Rocha NB, Telles-Correia D, Monteiro D, et al. https://pubmed.ncbi.nlm.nih.gov/31368874/

 

 

  • Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett PubMed. 2006 Aug 7 [cited 2021 Mar 2];580(18):4337–45. Murillo-Rodríguez E, Millán-Aldaco D, Palomero-Rivero M, Mechoulam R, Drucker-Colín R. https://pubmed.ncbi.nlm.nih.gov/16844117/

 

  • Effects of acute systemic administration of cannabidiol on sleep-wake cycle in rats. J Psychopharmacol [Internet]. 2013 Mar [cited 2021 Mar 2];27(3):312–6. Chagas MHN, Crippa JAS, Zuardi AW, Hallak JEC, MacHado-De-Sousa JP, Hirotsu C, et al. https://pubmed.ncbi.nlm.nih.gov/23343597/

 

CBD Y SALUD MENTAL 

 

 

 

 

 

 

 

 

 

  • Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl). PubMed. 2013 Apr [cited 2021 Mar 2];226(4):781–92. Das RK, Kamboj SK, Ramadas M, Yogan K, Gupta V, Redman E, et al. https://pubmed.ncbi.nlm.nih.gov/23307069/

 

  • Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. PubMed. 2012 [cited 2021 Mar 1];2(3). Leweke FM, Piomelli D, Pahlisch F, Muhl D, Gerth CW, Hoyer C, et al. https://pubmed.ncbi.nlm.nih.gov/22832859/

 

  • Cannabidiol Reduces the Anxiety Induced by Simulated Public Speaking in Treatment-Naı¨veNaı¨ve Social Phobia Patients. Neuropsychopharmacology. 2011 [cited 2021 Feb 25];36:1219–26. Bergamaschi MM, Helena Costa Queiroz R, Hortes M, Chagas N, Chaves Gomes De Oliveira D, De Martinis BS, et al. www.neuropsychopharmacology.org

 

  • Effectiveness of Cannabidiol Oil for Pediatric Anxiety and Insomnia as Part of Posttraumatic Stress Disorder: A Case Report. PubMed. 2016 Sep 1 [cited 2021 Mar 2];20(4):108–11. Shannon S, Opila-Lehman J. Perm J. https://pubmed.ncbi.nlm.nih.gov/27768570/

 

 

 

  • Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr. PubMed. 2012 Jun [cited 2021 Mar 1];34:S104–17. Schier AR de M, Ribeiro NP de O, e Silva AC de O, Hallak JEC, Crippa JAS, Nardi AE, et al. https://pubmed.ncbi.nlm.nih.gov/22729452/

 

  • Cannabidiol regulation of emotion and emotional memory processing: relevance for treating anxiety-related and substance abuse disorders . Vol. 174, British Journal of Pharmacology. John Wiley and Sons Inc.; PubMed. 2017 [cited 2021 Mar 1]. p. 3242–56. Lee JLC, Bertoglio LJ, Guimarães FS, Stevenson CW. https://pubmed.ncbi.nlm.nih.gov/28268256/

 

  • Pharmacological properties of cannabidiol in the treatment of psychiatric disorders: A critical overview. Vol. 27, Epidemiology and Psychiatric Sciences. Cambridge University Press; PubMed. 2018. p. 327–35. Mandolini GM, Lazzaretti M, Pigoni A, Oldani L, Delvecchio G, Brambilla P. https://pubmed.ncbi.nlm.nih.gov/29789034/

 

  • Cannabidiol as a Potential Treatment for Anxiety Disorders. Vol. 12, Neurotherapeutics. Springer New York LLC; PubMed.2015. p. 825–36. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. https://pubmed.ncbi.nlm.nih.gov/26341731/

 

 

CBD EN EL TRATAMIENTO DEL DOLOR Y LA INFLAMACIÓN

 

 

 

 

 

 

  • Antioxidants Antioxidative and Anti-Inflammatory Properties of Cannabidiol. [cited 2021 Feb 21]. Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. www.mdpi.com/journal/antioxidants

 

 

 

  • Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol [Internet]. PubMed. 2010 Dec 14 [cited 2021 Mar 1];56(25):2115–25. Rajesh M, Mukhopadhyay P, Btkai S, Patel V, Saito K, Matsumoto S, et al. https://pubmed.ncbi.nlm.nih.gov/21144973/

 

  • The effects of cannabidiol, a non-intoxicating compound of cannabis, on the cardiovascular system in health and disease [Internet]. Vol. 21, International Journal of Molecular Sciences. PubMed. 2020 [cited 2021 Mar 1]. p. 1–45. Kicman A, Toczek M. MDPI AG. https://pubmed.ncbi.nlm.nih.gov/32937917/

 

  • Cannabis-based medicines for chronic neuropathic pain in adults [Internet]. Vol. 2018, Cochrane Database of Systematic Reviews. John Wiley and Sons Ltd; PubMed. 2018 [cited 2021 Mar 1]. Mücke M, Phillips T, Radbruch L, Petzke F, Häuser W. https://pubmed.ncbi.nlm.nih.gov/29513392/

 

  • Burstein S. Cannabidiol (CBD) and its analogs: A review of their effects on inflammation. Vol. 23, Bioorganic and Medicinal Chemistry. Elsevier Ltd; PubMed. 2015. p. 1377–85.  https://pubmed.ncbi.nlm.nih.gov/25703248/

 

  • Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol. PubMed. 2017 [cited 2021 Mar 1];174(17):2832–41. King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker EA, et al. https://pubmed.ncbi.nlm.nih.gov/28548225/

 

  • Cannabidiol: A Brief Review of Its Therapeutic and Pharmacologic Efficacy in the Management of Joint Disease. Cureus. PubMed. 2020 Mar 23 [cited 2021 Mar 3];12(3). Gusho CA, Court T. https://pubmed.ncbi.nlm.nih.gov/32328386/

 

  • Self-management strategies amongst Australian women with endometriosis: A national online survey. Vol. 19, BMC Complementary and Alternative Medicine. BioMed Central Ltd.; PubMed. 2019. Armour M, Sinclair J, Chalmers KJ, Smith CA. https://pubmed.ncbi.nlm.nih.gov/30646891/

 

CBD Y EPILEPSIA

 

  • Cannabidiol: Its use in refractory epilepsies. Rev Neurol.. 2017 Aug 16 [cited 2021 Mar 1];65(4):157–60. Pesántez Ríos G, Armijos-Acurio L, Jimbo-Sotomayor R, Pascual-Pascual SI, Pesántez-Cuesta G. https://www.neurologia.com/articulo/2016573

 

  • Use of Cannabidiol in the Treatment of Epilepsy: Efficacy and Security in Clinical Trials. PubMed.[cited 2021 Mar 1]; Silvestro S, Mammana S, Cavalli E, Bramanti P, Mazzon E. https://pubmed.ncbi.nlm.nih.gov/31013866/

 

  • Cannabinoids and Epilepsy. Vol. 12, Neurotherapeutics. Springer New York LLC; PubMed.2015 [cited 2021 Mar 3]. p. 747–68. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. https://pubmed.ncbi.nlm.nih.gov/26282273/

 

 

 

  • Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia. PubMed. 2016 Oct 1 [cited 2021 Mar 1];57(10):1617–24. Hess EJ, Moody KA, Geffrey AL, Pollack SF, Skirvin LA, Bruno PL, et al. https://pubmed.ncbi.nlm.nih.gov/27696387/

 

  • Cannabidiol reduces seizures and associated behavioral comorbidities in a range of animal seizure and epilepsy models. Epilepsia. PubMed. 2019 Feb 1 [cited 2021 Mar 1];60(2):303–14. Patra PH, Barker-Haliski M, White HS, Whalley BJ, Glyn S, Sandhu H, et al. https://pubmed.ncbi.nlm.nih.gov/30588604/

 

  • Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results. Epilepsia. PubMed. 2018 Aug 1 [cited 2021 Mar 1];59(8):1540–8. Szaflarski JP, Bebin EM, Comi AM, Patel AD, Joshi C, Checketts D, et al. https://pubmed.ncbi.nlm.nih.gov/29998598/

 

 

  • Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy. Front Neurol. PubMed. 2019 Dec 10 [cited 2021 Mar 3];10. Klotz KA, Grob D, Hirsch M, Metternich B, Schulze-Bonhage A, Jacobs J. https://pubmed.ncbi.nlm.nih.gov/31920934/

 

  • Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. PubMed. 2014 [cited 2021 Mar 1];55(6):791–802. Devinsky O, Cilio MR, Cross H, Fernandez-Ruiz J, French J, Hill C, et al. https://pubmed.ncbi.nlm.nih.gov/24854329/

 

  • Epilepsy and cannabidiol: a guide to treatment. Epileptic Disord. PubMed. 2020 Feb 1 [cited 2021 Mar 3];22(1):1–14. Arzimanoglou A, Brandl U, Cross JH, Gil-Nagel A, Lagae L, Landmark CJ, et al. https://pubmed.ncbi.nlm.nih.gov/32096470/

 

 

CBD, ADICCIONES Y DESHABITUACIÓN

 

  • Cannabidiol rescues acute hepatic toxicity and seizure induced by cocaine. Mediators Inflamm. PubMed. 2015 [cited 2021 Mar 3];2015. Vilela LR, Gomides LF, David BA, Antunes MM, Diniz AB, De Araújo Moreira F, et al. https://pubmed.ncbi.nlm.nih.gov/25999668/

 

  • Unique treatment potential of cannabidiol for the prevention of relapse to drug use: preclinical proof of principle. Neuropsychopharmacology. PubMed. 2018 Sep 1 [cited 2021 Mar 3];43(10):2036–45. Gonzalez-Cuevas G, Martin-Fardon R, Kerr TM, Stouffer DG, Parsons LH, Hammell DC, et al. https://pubmed.ncbi.nlm.nih.gov/29686308/

 

  • Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage. PubMed. Vol. 12, Neurotherapeutics. Springer New York LLC; 2015 [cited 2021 Mar 3]. p. 807–15. Hurd YL, Yoon M, Manini AF, Hernandez S, Olmedo R, Ostman M et al. https://pubmed.ncbi.nlm.nih.gov/26269227/

 

  • The Potential of Cannabidiol Treatment for Cannabis Users with Recent-Onset Psychosis. PubMed. 2018 Jan 1 [cited 2021 Mar 3];44(1):46–53. Schizophr Bull [Internet]. Hahn B. https://pubmed.ncbi.nlm.nih.gov/29083450/

 

  • Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial. Epilepsy Behav. PubMed. 2018 Nov 1 [cited 2021 Mar 3];88:162–71. Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, et al. https://pubmed.ncbi.nlm.nih.gov/30286443/

 

  • The endocannabinoid system and cannabidiol’s promise for the treatment of substance use disorder. Front Psychiatry. PubMed.. 2019 [cited 2021 Mar 3];10(FEB). Chye Y, Christensen E, Solowij N, Yücel M. https://pubmed.ncbi.nlm.nih.gov/30837904/

 

  • Therapeutic prospects of cannabidiol for alcohol use disorder and alcohol-related damages on the liver and the brain [Internet]. Vol. 10, Frontiers in Pharmacology. Frontiers Media S.A.; PubMed. 2019 [cited 2021 Mar 3]. De Ternay J, Naassila M, Nourredine M, Louvet A, Bailly F, Sescousse G, et al. https://pubmed.ncbi.nlm.nih.gov/31214036/

 

  • The Potential of Cannabidiol as a Treatment for Psychosis and Addiction: Who Benefits Most? A Systematic Review. J Clin Med. PubMed. 2019 Jul 19 [cited 2021 Mar 3];8(7):1058. Batalla A, Janssen H, Gangadin SS, Bossong MG. https://pubmed.ncbi.nlm.nih.gov/31330972/

 

  • Cannabidiol treatment might promote resilience to cocaine and methamphetamine use disorders: A review of possible mechanisms [Internet]. Vol. 24, Molecules. MDPI AG; PubMed. 2019 [cited 2021 Mar 3]. Calpe-López C, Pilar García-Pardo M, Aguilar MA. https://pubmed.ncbi.nlm.nih.gov/31315244/

 

 

CBD Y FUNCIONES COGNITIVAS

 

  • Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur Neuropsychopharmacol. PubMed. 2017 Aug 1 [cited 2021 Mar 3];27(8):795–808. Cooper RE, Williams E, Seegobin S, Tye C, Kuntsi J, Asherson P. https://pubmed.ncbi.nlm.nih.gov/28576350/

 

  • Modulation of cognitive and emotional processing by cannabidiol: The role of the anterior cingulate cortex. Front Hum Neurosci. PubMed. 2013 Apr 4 [cited 2021 Mar 3];7(APR 2013). Kowal MA, Hazekamp A, Colzato LS, van Steenbergen H, Hommel B. https://pubmed.ncbi.nlm.nih.gov/23616760/

 

  • Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial. Cannabis Cannabinoid Res. PubMed. 2018 Mar 1 [cited 2021 Mar 3];3(1):21–34. Solowij N, Broyd SJ, Beale C, Prick JA, Greenwood LM, Van Hell H, et al. https://pubmed.ncbi.nlm.nih.gov/29607408/

 

CBD Y OSTEOPOROSIS 

 

 

 

  • Cannabinoids and the skeleton: From marijuana to reversal of bone loss.  Vol. 41, Annals of Medicine. Ann Med; PubMed. 2009 [cited 2021 Mar 3]. p. 560–7. Bab I, Zimmer A, Melamed E. https://pubmed.ncbi.nlm.nih.gov/19634029/

 

  • Cannabidiol, a Major Non-Psychotropic Cannabis Constituent Enhances Fracture Healing and Stimulates Lysyl Hydroxylase Activity in Osteoblasts. J Bone Miner Res. PubMed. 2015 Oct 1 [cited 2021 Mar 3];30(10):1905–13. Kogan NM, Melamed E, Wasserman E, Raphael B, Breuer A, Stok KS, et al. http://doi.wiley.com/10.1002/jbmr.2513

 

  • Cannabinoid Receptors as Target for Treatment of Osteoporosis: A Tale of Two Therapies. Curr Neuropharmacol. PubMed. 2010 Aug 19 [cited 2021 Mar 3];8(3):243–53. I. Idris A. https://pubmed.ncbi.nlm.nih.gov/21358974/

 

  • Protective effects of cannabidiol on lesion-induced intervertebral disc degeneration. PLoS One. PubMed. 2014 Dec 17 [cited 2021 Mar 3];9(12). Silveira JW, Issy AC, Castania VA, Salmon CEG, Nogueira-Barbosa MH, Guimarães FS, et al. https://pubmed.ncbi.nlm.nih.gov/25517414/

 

CBD Y AFECCIONES DE LA PIEL

 

  • Cannabis sativa L. extract and cannabidiol inhibit in vitro mediators of skin inflammation and wound injury. Phyther Res. PubMed. 2019 Aug 1 [cited 2021 Mar 1];33(8):2083–93. Sangiovanni E, Fumagalli M, Pacchetti B, Piazza S, Magnavacca A, Khalilpour S, et al. https://pubmed.ncbi.nlm.nih.gov/31250491/

 

  • Therapeutic potential of cannabidiol (CBD) for skin health and disorders. Clin Cosmet Investig Dermatol. PubMed. 2020 [cited 2021 Mar 1];13:927–42. Baswan SM, Klosner AE, Glynn K, Rajgopal A, Malik K, Yim S, et al. https://pubmed.ncbi.nlm.nih.gov/33335413/

 

  • A therapeutic effect of cbd-enriched ointment in inflammatory skin diseases and cutaneous scars. Clin Ter. PubMed. 2019 Mar 1 [cited 2021 Mar 1];170(2):E93–9. Palmieri B, Laurino C, Vadala M. https://pubmed.ncbi.nlm.nih.gov/30993303/

 

  • The antimicrobial potential of cannabidiol. Commun Biol. PubMed. 2021 Dec 1 [cited 2021 Mar 1];4(1). Blaskovich MAT, Kavanagh AM, Elliott AG, Zhang B, Ramu S, Amado M, et al. https://pubmed.ncbi.nlm.nih.gov/33469147/

 

  • The Differential Effect of Cannabidiol on the Composition and Physicochemical Properties of Keratinocyte and Fibroblast Membranes from Psoriatic Patients and Healthy People. Membranes (Basel). PubMed. 2021 Feb 4 [cited 2021 Mar 1];11(2):111. Szachowicz-Petelska B, Łuczaj W, Wroński A, Jastrząb A, Dobrzyńska I. https://pubmed.ncbi.nlm.nih.gov/33557204/

 

  • Cannabidiol effects on phospholipid metabolism in keratinocytes from patients with Psoriasis Vulgaris. Biomolecules- PubMed. 2020 Mar 1 [cited 2021 Mar 1];10(3). Jarocka-Karpowicz I, Biernacki M, Wroński A, Gęgotek A, Skrzydlewska E. https://pubmed.ncbi.nlm.nih.gov/32121131/

 

  • Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes. J Clin Invest. PubMed. 2014 Sep 2;124(9):3713–24. Oláh A, Tóth BI, Borbíró I, Sugawara K, Szöllõsi AG, Czifra G, et al. https://pubmed.ncbi.nlm.nih.gov/25061872/

 

CBD Y ESCLEROSIS MÚLTIPLE

 

  • Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells. Front Immunol. PubMed. 2018 Aug 3 [cited 2021 May 12];9(AUG). Elliott DM, Singh N, Nagarkatti M, Nagarkatti PS. https://pubmed.ncbi.nlm.nih.gov/30123217/

 

  • Symptomatic therapy in multiple sclerosis: The role of cannabinoids in treating spasticity [Internet]. Vol. 5, Therapeutic Advances in Neurological Disorders. Ther Adv Neurol Disord; PubMed. 2012 [cited 2021 May 12]. p. 255–66. Leussink VI, Husseini L, Warnke C, Hartung HP, Broussalis E, Kieseier BC. https://pubmed.ncbi.nlm.nih.gov/22973422/

 

  • Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: A systematic review. BMC Neurol. PubMed. 2009 Dec 4 [cited 2021 May 12];9. Lakhan SE, Rowland M. https://pubmed.ncbi.nlm.nih.gov/19961570/

 

  • Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review [Internet]. Vol. 16, Journal of Neuroimmune Pharmacology. Springer; PubMed. 2021 [cited 2021 May 12]. Furgiuele A, Cosentino M, Ferrari M, Marino F. https://pubmed.ncbi.nlm.nih.gov/33492630/

 

  • Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. PubMed. Vol. 9, Therapeutic Advances in Neurological Disorders. Ther Adv Neurol Disord; 2016 [cited 2021 May 12]. p. 9–30. Zettl UK, Rommer P, Hipp P, Patejdl R. https://pubmed.ncbi.nlm.nih.gov/26788128/

 

  • Advances in the management of multiple sclerosis spasticity: Multiple sclerosis spasticity nervous pathways. Eur Neurol. PubMed. 2014 Nov 7 [cited 2021 May 12];72:6–8. Centonze D. https://pubmed.ncbi.nlm.nih.gov/25278116/

 

  • Purified Cannabidiol, the main non-psychotropic component of Cannabis sativa, alone, counteracts neuronal apoptosis in experimental multiple sclerosis – PubMed. [cited 2021 May 12]. S Giacoppo, T Soundara Rajan, M Galuppo, F Pollastro, G Grassi, P Bramanti, E Mazzon. https://pubmed.ncbi.nlm.nih.gov/26744883/

 

 

  • Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice. Br J Pharmacol. PubMed. 2011 Aug [cited 2021 May 12];163(7):1507–19. Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, et al. https://pubmed.ncbi.nlm.nih.gov/21449980/

 

  • Cannabidiol to improve mobility in people with multiple sclerosis [Internet]. Vol. 9, Frontiers in Neurology. Frontiers Media S.A.; PubMed. 2018 [cited 2021 May 12]. Rudroff T, Sosnoff J. https://pubmed.ncbi.nlm.nih.gov/29623067/

 

  • Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors. Neurobiol Dis. PubMed. 2013 Nov [cited 2021 May 12];59:141–50. Mecha M, Feliú A, Iñigo PM, Mestre L, Carrillo-Salinas FJ, Guaza C. https://pubmed.ncbi.nlm.nih.gov/23851307/

 

CBD Y CANCER

 

 

 

  • Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. Molecular Cancer. PubMed. 2010, 9:196, doi:10.1186/1476-4598-9-196. María M. Caffarel, Clara Andradas, Emilia Mira, Eduardo Pérez-Gómez, Camilla Cerutti, Gema Moreno-Bueno, Juana M. Flores, Isabel García-Real, José Palacios, Santos Mañes, Manuel Guzmán y Cristina Sánchez. https://pubmed.ncbi.nlm.nih.gov/20649976/